Here are some of the latest health and medical news
developments, compiled by the editors of HealthDay:
Makers of Brand-Name Opioid Painkillers Fight New Generics
As the makers of generic versions of opioid painkillers prepare
to bring their cheaper products to market this month, the companies
that produce brand-name versions of these powerful medications
continue to fight the effort.
According to a report published in
The New York Times, both Purdue Pharma and Endo
Pharmaceuticals have introduced tamper-resistant versions of
Oxycontin and Opana that are difficult to crush or melt, so it's
harder for people to abuse the drugs. Both companies claim the move
was motivated by concerns for public safety, and the companies have
asked the U.S. Food and Drug Administration to require the same
tamper-resistant design from the generic drug makers.
So far, their efforts have been stymied. Last month, a federal
judge dismissed a lawsuit filed by Endo that would have kept
generic versions of its drug, Opana, from going on sale in January.
In court papers, the FDA said the lawsuit was a "thinly veiled
attempt [by Endo] to maintain its market share and block generic
Dr. Douglas C. Throckmorton, deputy director of regulatory
programs at the FDA, told the
Timesthat a guidance is expected to be issued this month
that would detail what kind of data would be required to show that
a tamper-resistant design would make an opioid painkiller more
difficult to abuse.
"We understand the value in developing appropriate abuse-resistant technology, and we want to find a way of incentivizing that," Throckmorton said. "But we also understand the value of generics for patients."
One recent study, funded by Purdue Pharma and published in the
Journal of Pain, did find that the number of people treated
at drug-abuse clinics who said they had abused Oxycontin fell
significantly following the introduction of the tamper-resistant
version of the painkiller.
One expert told the
Timesthat the issue is complicated.
"I think it is great that the industry is creating innovative strategies," said Dr. Daniel Alford, a professor at the Boston University School of Medicine. "But these drugs are expensive." He also noted that the labeling of any potentially dangerous drug as being safer could eventually lead to other safety problems.
Quitting Smoking May Lower Anxiety Levels
Quitting smoking may lower anxiety levels, British researchers
Almost 500 smokers who were trying to quit were followed for six
months, and the 68 who were successful at that point also showed
lower anxiety levels, the
Scientists from Cambridge, Oxford and King's College in London,
who published their findings in the
British Journal of Psychiatry, did note that those who had
mood or anxiety disorders were more likely to show this effect and
that those who tried to quit but failed showed slight increases in
However, those who smoked only for pleasure did not become more
anxious if their efforts to quit failed, the researchers added.
New Law Would Fund 'Bubble Boy' Treatment at Home
Treatments for people with a primary immunodeficiency disease,
or "bubble boy disease," may soon become more accessible and
affordable. If signed into law by President Obama, a bill passed by
the House and Senate last week would fund at-home drug therapy for
Patients with primary immunodeficiency diseases can't fight
everyday germs and viruses. To obtain the antibodies needed to stay
alive, they require frequent hospital visits for intravenous
immunoglobulin treatments. But hospitals harbor potentially deadly
germs and are often a long way from home.
Last week, the House and Senate passed the Medicare IVIG Access
Act, which provides for a three-year pilot program with at-home
infusions paid for by Medicare,
ABC Newsreported. Previously, the infusion drugs were
covered, but not the ancillary services, including nursing.
Dr. Michael Blaese, medical director of the Immune Deficiency
Foundation, called that omission a "quirk," and said the treatments
are essential. "If they don't get it, they get infected, and they
die of pneumonia, meningitis, septicemia," he told
ABC News. Or they suffer from lifelong lung damage, he
In the United States, about 250,000 people have primary
immunodeficiency diseases. The bill was reportedly inspired by the
late David Vetter of Texas, the original "boy in the bubble" who
lived in a sterile plastic bubble until his death at age 12.
Ex-President George H.W. Bush in Hospital ICU: Reports
Former President George H.W. Bush, 88, remains in "guarded
condition" in the intensive care unit at a Houston hospital because
of a persistent fever related to a lingering respiratory illness,
according to published reports.
Bush, who was initially hospitalized on Nov. 23 with a cough
linked to bronchitis, was moved to the ICU at Methodist Hospital on
Sunday because of an alarming fever, Jim McGrath, Bush's spokesman
in Houston, told the
"It's an elevated fever, so it's actually gone up in the last day or two," McGrath told the AP. "It's a stubborn fever that won't go away." However, the cough that sent Bush to the hospital last month is improved, he said.
Bush -- the 41st president and the oldest former
commander-in-chief -- was put on a liquid diet, McGrath also said
on Wednesday. The former president's family is with him, and his
physicians are cautiously optimistic about his prognosis, McGrath
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.